Overview

Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients

Status:
Unknown status

Trial end date:
2014-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to demonstrate non-inferiority of micafungin at a dose of 100 mg/day versus fluconzeole for the prevention of Invasive Fungal Disease, defined according to the revised EORTC/MSG criteria, undergoing living-donor liver transplantation.

Phase:

Phase 3

Details

Lead Sponsor:

Asan Medical Center

Treatments:

Echinocandins
Fluconazole
Micafungin